Home Blog Page 1482

Oudomxay Province Inaugurates Laos’ Largest Solar Power Project

By
Thongsavanh Souvannasane
-
A 1,000 MW solar power facility in Oudomxay Province, one of the country’s largest renewable energy projects. (Photo credit: CGN Energy Laos)

Oudomxay Province on 13 December officially inaugurated a 1,000-megawatt solar power project, marking one of Laos’ largest renewable energy developments to date. The facility was developed by CGN Energy Technology (Laos) Co., Ltd. in partnership with the Lao government.

The project was launched under a concession agreement signed in September 2024, with construction beginning the same month. Approximately 800 technical specialists and laborers worked across 2,090 hectares covering seven villages in Xay and Namor districts. Before commissioning, the project completed full land clearing and landmine removal, while making significant progress on internal roads and electrical infrastructure.

During a site inspection on 29 May, Oudomxay Governor Bounkhong Lachiemphon reviewed ongoing construction, confirming that clearing was fully completed, landmine clearance had reached 95.74 percent, internal roads were more than 81 percent finished, and electrical pole installation was nearing 60 percent. 

Solar panel deployment had begun, with mounting structures at 3.56 percent and panel installation at 1.89 percent. Transmission infrastructure preparations, including surveys and site confirmation for 43 pole bases, were also underway.

Once fully operational, Phase I of the project is expected to generate approximately 1.7 billion kilowatt-hours of electricity annually, enough to supply power to roughly 10 million households. The electricity will be transmitted to China’s Yunnan Province via the China–Laos 500-kilovolt power grid interconnection, supporting regional energy transition efforts and enhancing cross-border power supply stability.

The solar farm is also expected to deliver socio-economic benefits to local communities, including job creation, vocational training, and improved infrastructure for surrounding villages.

The project forms a central part of the Northern Laos Interconnected Clean Energy Base, which integrates solar, wind, and biomass power projects across Oudomxay, Luang Namtha, and Phongsaly provinces. The initiative aims to establish northern Laos as a regional clean energy hub.

Solar Power Growth Surges in Laos

In a broader effort to national development, Laos is accelerating its renewable energy expansion with several new solar power projects across the country, involving partnerships with South Korean and U.S. companies.

On 10 November, the state-run utility Electricité du Laos (EDL) signed an agreement with South Korean firm CS Tech Co., Ltd. to develop floating solar installations on its hydropower reservoirs. The partnership will also explore carbon credit initiatives to support Laos’ climate goals.

Earlier in August, EDL reached agreements with another South Korean company, ASFC Co., Ltd., to build a 15-megawatt solar project near several of its hydropower plants, including Xeset 1-3, Xelabam, and Nam Mang 3.

In southern Laos, the provincial government of Attapeu approved a 5-megawatt solar power project on 28 October, to be developed by South Korean firm SBIN Corporation. The project will cover 10 hectares in Sanongmai-Piandong village, Sanamxay district.

Meanwhile, U.S.-based Convalt Energy is developing a large-scale 1,200-megawatt solar farm in Attapeu, representing an investment of USD 1.3 billion. The facility will span approximately 1,800 hectares, making it one of the largest solar projects in the country.

These initiatives, alongside ongoing developments in northern provinces aim to diversify the nation’s energy mix, reduce reliance on fossil fuels, and strengthen cross-border energy cooperation in the region.

ORGE Co., Ltd. Enters Japan’s Organic Health Food Market, Strengthening Strategy to Capture Local Wellness Trends

By
Advertorial Desk
-

SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ — ORGE Co., Ltd., a Korean brand specializing in organic health foods, is accelerating its push into the Japanese market, marking a new phase in its global expansion. In November, ORGE participated in the Japan Food Tech Fair held at Tokyo Big Sight, where it engaged in partnership discussions with major Japanese distributors and health food buyers. Building on these talks, the company has announced plans for an official launch in Japan in the first half of next year.

ORGE’s flagship lineup of organic, low-sodium health-focused samgyetang (Korean ginseng chicken soup) received positive feedback from local buyers, aligning well with Japan’s rapidly growing demand for wellness-oriented convenience foods. Emphasizing ease of preparation and the use of safe, domestically sourced Korean ingredients, ORGE’s products are expected to gain strong appeal among busy office workers and Japan’s expanding single-person household segment.

The company also unveiled Japan-exclusive menu concepts tailored to local consumer preferences. These include a light soup line featuring a milder, smoother broth profile, as well as meal-replacement options with localized ratios of organic chicken. Strong interest at the event underscored the potential for expanding a dedicated Japan-only product portfolio.

ORGE is currently in discussions regarding private brand (PB) collaborations with Japanese convenience store chains and potential placement in premium supermarkets in the Tokyo and Osaka areas. The company is also reviewing listings on major e-commerce platforms such as Rakuten and Amazon Japan. In addition, ORGE plans to operate pop-up stores in key Japanese cities to strengthen brand awareness and broaden consumer touchpoints.

An ORGE representative stated, “We aim to establish a stable foothold in Japan by reinforcing localization strategies that reflect Japanese dietary habits and high quality standards. Our goal is to grow into a premium organic health food brand representing K-food and to expand our presence across Asia.”

Agricultural Corporation Joeunsul Co., Ltd. Announces Entry into Vietnam Market, Accelerating Southeast Asia Expansion with “Cheonbihyang”

By
Advertorial Desk
-

SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ — Korean traditional liquor producer Agricultural Corporation Joeunsul Co., Ltd. has announced its plans to enter the Vietnamese market, spearheading its Southeast Asia expansion with its flagship traditional rice wine, Cheonbihyang. The company is currently exploring Vietnam as a new export destination, amid the region’s growing interest in diverse food cultures and a steady rise in international tourism. Joeunsul is reviewing local import procedures and consulting with potential distribution partners to establish a fully compliant and legal distribution network.

Cheonbihyang is a premium yakju brewed from domestically sourced glutinous and non-glutinous rice, combined with traditional Korean nuruk, and refined through an extended fermentation process. Known for its smooth aroma and refined mouthfeel, the product received the Presidential Award at Korea’s most prestigious liquor competition in 2025, officially recognizing its quality and authenticity. This distinction is expected to serve as a strong credibility marker when engaging overseas buyers.

Vietnam enforces strict regulations on imported alcoholic beverages, including distribution approvals, quality inspections, import licensing, and compliance with sealing and labeling requirements. Joeunsul is proactively reviewing these regulations and preparing for lawful import procedures. In parallel, the company is considering an initial distribution strategy focused on premium hotels and restaurants in major cities such as Ho Chi Minh City and Hanoi, where demand for high-end international beverages is concentrated.

A Joeunsul representative stated, “Cheonbihyang is not merely an alcoholic beverage, but a true expression of Korea’s fermentation heritage. Through this entry into Vietnam, we aim to compete on quality and storytelling, serving as a bridge to introduce K-traditional liquor to the Southeast Asian market.”

As Korean traditional liquor continues to seek new growth opportunities abroad, industry attention is focused on how Cheonbihyang will be received by Vietnamese consumers and whether this initiative will mark a meaningful step forward for K-traditional spirits in Southeast Asia.

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

By
Advertorial Desk
-
GENEVA, SWITZERLAND – EQS Newswire – 15 December 2025 – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases. The newly combined entity now operates under the name MindMaze Therapeutics Holding SA.

The closing follows the signing of a definitive business combination agreement in October 2025 and subsequent shareholder approval at the Company’s extraordinary general meeting in November. The transaction establishes a fully integrated company with a first-of-its-kind ecosystem, uniting precision digital neurotherapeutics, pharmacological treatments, cutting-edge devices, data, and an AI-powered platform, positioned to redefine neurological care and change patient lives.

“Neurological diseases are one of the leading causes of disability globally,” said Olaf Blanke (MD), member of the Board of Directors, Professor of Neuroscience and Cognitive Neuroprosthetics at the Swiss Federal Institute of Technology (EPFL) and Adjunct Professor at the Department of Clinical Neurosciences at the University Hospital of Geneva. “The situation is worsening due to aging populations, with 1 in 6 people expected to develop a neurological disease, making the need for effective, scalable solutions more urgent than ever. While neuro-rehabilitation requires intensive, repetitive training for functional recovery, traditional healthcare systems often fail to deliver adequate therapy, leaving millions of patients without optimal treatment. MindMaze Therapeutics seeks to address this gap by providing clinically proven neurotherapeutics to support their recovery journey, from hospital to rehab center to their home.”

“Today begins a new chapter for MindMaze Therapeutics,” commented Walid Hanna, Chairman of the Board of Directors of MindMaze Therapeutics. “The company is founded on clinically validated innovation, and driven by a mission to transform neurological care, addressing a critical and persistent gap in motor and cognition restorations in neurological conditions. We are now focused on advancing our precision neurotherapeutics platform to deliver impact at scale. Relief’s complementary capabilities and biopharmaceutical assets strengthen our growth strategy, supporting both drug-digital integration and expanding development opportunities.”

MindMaze Therapeutics acquired NeuroX through a share exchange in which all outstanding shares of NeuroX were contributed by its former shareholders in exchange for 140,000,000 newly issued ordinary shares of the Company. These new shares will be admitted to trading and listing on the SIX Swiss Exchange today, in accordance with the approved prospectus and applicable regulations. Effective immediately, all listed ordinary shares of the Company will trade under the updated ticker symbol MMTX. Following the transaction, the total number of outstanding shares amounts to 152,602,044, excluding treasury shares.

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company’s ability to execute its strategy and secure sufficient resources to support its operations. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Additional features:
File: Ad hoc release_MindMaze_Closing Business Combination

The issuer is solely responsible for the content of this announcement.

ABOUT MINDMAZE THERAPEUTICS

MindMaze Therapeutics is a Swiss-based, commercial-stage company formed in December 2025 through the business combination of RELIEF THERAPEUTICS Holding SA (Relief) and NeuroX Group SA. The Company develops and commercializes first-of-its-kind digital treatments for neurological diseases and brain disorders. Built on an advanced brain technology platform integrating software, sensors, and telehealth, its solutions are deployed globally across clinics and home settings. MindMaze Therapeutics’ clinically validated neurotherapeutics have demonstrated significant medico-economic outcomes across conditions such as stroke, Parkinson’s disease, and at-risk aging. The Company continues to expand its R&D pipeline into adjacent neurological indications, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer’s disease.

The Company also manages Relief’s preexisting portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.

MindMaze Therapeutics is listed on the SIX Swiss Exchange under the ticker and quoted in the U.S. on OTCQB under and .

For more information, visit .

LifeWave Highlights Five Key Focus Areas at Taiwan-Hong Kong-Macau Annual Conference, Featuring a Boundary-Breaking Indoor Drone Opening

By
Advertorial Desk
-

TAIPEI, Dec. 15, 2025 /PRNewswire/ — LifeWave hosted the SHARE THE LIGHT Taiwan–Hong Kong–Macau Annual Recognition Conference on December 14 at the Taipei International Convention Center, bringing together nearly 2,000 Brand Partners and guests. The event marked a milestone, reflecting LifeWave’s 17 years of growth and market development in Taiwan.

LifeWave Highlights Five Key Focus Areas at Taiwan–Hong Kong–Macau Annual Conference, Featuring a Boundary-Breaking Indoor Drone Opening
LifeWave Highlights Five Key Focus Areas at Taiwan–Hong Kong–Macau Annual Conference, Featuring a Boundary-Breaking Indoor Drone Opening

The conference opened with an innovative drone light performance that brought large-scale drone formations—traditionally seen outdoors—onto an indoor stage. Through cross-venue technology integration, the performance demonstrated new possibilities for live events and reflected LifeWave’s commitment to innovation and its “Unlimited” approach to technology application.

The event was attended by LifeWave’s Asia-Pacific President and North America Vice President, underscoring the company’s strong commitment to the Taiwan–Hong Kong–Macau market and highlighting the region’s strategic role in LifeWave’s global expansion.

Five Key Highlights Define LifeWave’s Annual Vision

Technology Vision
LifeWave outlined future application directions for its light-based wellness technology, including ongoing research and development progress, global expansion initiatives, and future product strategies. These efforts reinforce the company’s long-term commitment to innovation in health technology.

System Enhancement
Following the global launch of Compensation Plan 2.0, the Taiwan–Hong Kong–Macau market has emerged as one of the leading performers in the Asia-Pacific region for advancement activity. Since the new compensation was introduced on October 27, the number of partners receiving bonuses increased by approximately 40 percent within the first seven weeks, with more than 3,000 partners achieving rank advancements.

LifeWave noted that the latest system optimization focuses on transparency, competitiveness, and growth momentum, helping partners gain greater clarity in managing their business rhythm.

Market Insights
Leaders from multiple international markets shared frontline perspectives, offering diverse insights into global trends and enabling Taiwan–Hong Kong–Macau partners to stay aligned with international market developments.

Sports Application
A former professional baseball player and Masters Games bronze medalist shared firsthand experiences from training preparation through post-competition recovery, illustrating how light-based technology is incorporated into real-world sports scenarios.

Cultural Highlight
Renowned entertainer Janice Wang, together with the iconic Third Prince (San Tai Zi) performance, brought vibrant cultural energy to the conference, creating a memorable moment that blended technology, systems, and entertainment.

Extending the “Share the Light” Initiative
As part of its ongoing “Share the Light” initiative, LifeWave partnered once again with long-term charity collaborator SimplyICR to launch a limited edition of 1,000 charity gift boxes, which received strong market support. Proceeds will be used to fund art education and creative resources for SimplyICR students, transforming goodwill into sustainable impact.

Looking Ahead with an Unlimited Vision
Scarlett Su, General Manager of LifeWave Taiwan–Hong Kong–Macau, said:
“‘Share the Light’ represents our willingness to bring light to others, while ‘Unlimited’ reflects our commitment to openness, forward-thinking, and courage as we look to the future. With a broader global perspective, we will continue expanding LifeWave’s impact—illuminating markets, partners, communities, and every possibility worth being seen.”

About LifeWave
Founded in 2004 and headquartered in the United States, LifeWave established its Taiwan branch in 2008. The company is dedicated to advancing light-based wellness innovation through research and product development. Its patented light-based technology, including the flagship X39 product, represents a key milestone in LifeWave’s global development. Today, LifeWave operates in more than 80 international markets, continuing its mission to enhance human well-being through science and innovation.

Viva Biotech’s invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.

By
Advertorial Desk
-

STOCKHOLM, Dec. 15, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first half of 2026.

Viva Biotech expects that the Merger will result in an aggregate gain of approximately US$40.0 million. The exact amount will depend on the fulfilment of regulatory and performance milestones. In addition, Arthrosi has also entered into new statement of work (SOW) with the Viva Biotech’s CDMO business unit (Langhua Pharmaceutical) for the supply of active pharmaceutical ingredient, and the Group expects to continue its business cooperation with Arthrosi.

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients. The acquisition strengthens Sobi’s gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad complements Sobi’s pipeline by adding a potentially best-in-class URAT1 inhibitor for patients sub-optimally treated with first-line therapies. Today’s announcement reflects Sobi’s commitment to advancing treatment options for people living with gout.

“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset”, said Guido Oelkers, President and CEO of Sobi. “Pozdeutinurad has the potential to become the therapy of choice for patients who have progressive gout with persistent and unresolved symptoms despite first-line therapy. The product has the potential to materially accelerate our growth until the mid 2030s, and beyond. We welcome all members of the talented Arthrosi team and are looking forward to working closely together to be able to offer this therapy to patients as soon as possible.”

“We are thrilled to join forces with Sobi and look forward to working together to ensure a seamless transition as they advance pozdeutinurad towards pivotal data and potential regulatory filings. We believe that Sobi’s global expertise in commercialization will accelerate our shared mission to deliver pozdeutinurad’s potentially transformative benefits for individuals living with gout”, stated Litain Yeh, Ph.D., Founder and CEO of Arthrosi Therapeutics.

Dr. Han Dai, Chief Innovation Officer and Head of Viva BioInnovator commented “We are very pleased to see Arthrosi reach this milestone with the acquisition by Sobi. Viva Biotech started to participated in Arthrosi from the seed round onward and remained a long-term investors across multiple subsequent rounds. As an industrial partner, Viva Biotech has also maintained long-term and in-depth collaboration with the team in areas across R&D, manufacturing, and global industry resource integration. We have witnessed Arthrosi’s continued focus on solving the unmet medical need of gout, marked by clear and disciplined scientific and clinical decision-making. This acquisition fully reflects the dual realization of industrial and clinical value, further validating the feasibility of Viva Biotech’s investment and industry empowerment model in the global innovative drug sector. We sincerely congratulate Arthrosi and Sobi on their collaboration, and extend sincere congratulations to the two founders of Arthrosi — Dr. Litain Yeh and Dr. Shunqi Yan. We look forward to the continued long-term value creation of this project within a larger industrial platform. And we also thank ApicHope and all shareholders for their continued support and trust throughout the company’s journey.”

About Arthrosi

Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with progressive gout. The rights to pozdeutinurad in Greater China are held by ApicHope.

About Sobi

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion.

About Viva Biotech

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

Festive Fares: Agoda Reveals Asia’s Most Affordable Year-End Flight Routes for Holiday Travelers

By
Advertorial Desk
-

SINGAPORE, Dec. 15, 2025 /PRNewswire/ — As the year-end holiday season approaches, digital travel platform Agoda reveals the most affordable domestic and international flight routes across Asia. The list offers travelers insights into the routes that could offer a chance to celebrate without breaking the bank. Based on bookings made from September 2025 onwards for departures between December 20-31, Agoda reveals Thailand was the top destination for budget-friendly domestic flights, with fares starting as low as 6 USD. For international journeys, Malaysia and Indonesia share the spotlight, having offered flights during this period from just 25 USD.

The Christmas and New Year’s holiday season is one of the most significant travel periods of the year. With schools on break and many workplaces offering extended holidays, travelers seize the opportunity to embark on journeys, whether to reunite with family, explore new destinations, or simply unwind and spend quality time with loved ones. This convergence of cultural celebrations and vacation time off makes it one of the busiest and most cherished travel periods of the year, and for many travelers, it’s more important than ever to find the best deals to maximize the holiday experience.

In the realm of domestic travel, Thailand stood out for having the most affordable flights, such as the Udon Thani to Bangkok route booked at 6 USD. This makes it an excellent choice for those eager to experience Bangkok’s vibrant holiday atmosphere, when the city comes alive with dazzling lights, festive markets, and cultural celebrations. Following closely are South Korea and Malaysia, with fares that were available at 9 USD for routes like Jeju to Seoul and Bario to Miri. Completing the ranks for the most economical domestic flights were India (15 USD), Indonesia (18 USD), Vietnam (22 USD), Japan (25 USD), and Taiwan (45 USD).

For international travel, Malaysia and Indonesia tied for the most budget-friendly fares, with flights from Johor Bahru to Phuket and Pontianak to Kuching offered at 25 USD. These routes provide perfect escapes to sunny islands and lush nature during the holiday season. Thailand follows in second place with flights from Krabi to Kuala Lumpur booked from 28 USD. Completing the list are South Korea (32 USD), Japan (39 USD), Taiwan (46 USD), Vietnam (46 USD), and India (73 USD).

Andrew Smith, Senior Vice President of Supply at Agoda shared, “At Agoda, we’re excited to open up a world of possibilities with our extensive flight options this holiday season. During the busy Christmas and New Year period, budget-friendly flights are crucial to making the most of the festive season. Whether you’re reuniting with family, chasing the sun on a tropical island, or embarking on a new adventure, we’ve got the perfect flight to make your holiday dreams come true.”

With over 130,000 flight routes, more than 6 million holiday properties, and over 300,000 activities, Agoda ensures travelers can seamlessly combine their bookings in one convenient platform for a memorable holiday experience. Discover the best deals on Agoda’s mobile app and visit Agoda.com to plan the perfect festive getaway.

Counterfeit “Sagami Original” Condoms Discovered Overseas

By
Advertorial Desk
-

ATSUGI, Japan, Dec. 15, 2025 /PRNewswire/ — Sagami Rubber Industries, Co., Ltd. of Japan has announced the discovery of counterfeit packages of its “flagship” product Sagami Original 0.01 Polyurethane condoms overseas.

“We will keep on strengthening measures against counterfeit products. Meanwhile, we kindly ask customers to exercise caution to avoid purchasing counterfeit items,” the company said in a statement.

— How to Identify Genuine vs Counterfeit Sagami Original Condoms

Sagami has prepared the following points which have been confirmed over several inspections of boxes of counterfeit condoms. These points provide differences between the packaging and contents of genuine and counterfeit products.

Image1: https://cdn.kyodonewsprwire.jp/prwfile/release/M108923/202512040402/_prw_PI1fl_0ILLnI48.jpg 

1. Packaging Appearance

Packaging: Front

– Sagami Original Logo: A red-foil “sagami original” logo has more rounded letters.

Image2: https://cdn.kyodonewsprwire.jp/prwfile/release/M108923/202512040402/_prw_PI2fl_5z4wnIGf.jpg 

– Diagonal Sticker

Image3: https://kyodonewsprwire.jp/attach/202512040402-O3-x2rVj82B.pdf 

Packaging: Back

Image4: https://kyodonewsprwire.jp/attach/202512040402-O1-gser53Ft.pdf 

2. Condom Itself (Thickness, Shape, etc.)

Shape and Tip Form

– The condom shape of the semen reservoir tip is designed differently.

– The genuine product has a more gradual sheath shape, while the counterfeit product has a rounded one.

Image5: https://cdn.kyodonewsprwire.jp/prwfile/release/M108923/202512040402/_prw_PI4fl_mDtSK5Yn.jpg 

Thickness and Dimensions

– Average thickness (mm): Genuine: 0.01, Counterfeit: 0.03

– Length (mm): Genuine: 175.3, Counterfeit: 171.0

– Weight (g): Genuine: 0.699, Counterfeit: 0.462

3. Instruction Sheet (Chinese characters in Japanese text)

Image6: https://kyodonewsprwire.jp/attach/202512040402-O2-L9KN4kR5.pdf 

Remarks

– Sagami strongly urges customers to avoid purchasing counterfeit products and to purchase its product from authorized sales channels.

– Counterfeit items are not manufactured or sold by the company, so it cannot guarantee their quality or safety.

– Please note that Sagami is unable to investigate authenticity, provide replacements, or compensate for damages related to products purchased through unauthorized channels. The company appreciates customers’ understanding.

1...1,4811,4821,483...6,446Page 1,482 of 6,446